LONP1 and fibrosarcoma: Finally, while LonP1 siRNA was not possible to significantly interfere with cell movement, treatment with CDDO-Me was found to decrease the motility of fibrosarcoma and metastatic melanoma cells, suggesting that LonP1 could be a potential target for cancer therapy in these cells.